DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Positive New Data From Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of AT-01 (Iodine I-124 evuzamitide), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of multiple types of systemic amyloidosis. These data were included in oral and poster presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting taking place June 11-14, 2022, in Vancouver, BC, Canada.
The Phase 1/2 trial evaluated the ability of AT-01 to detect amyloid deposits by PET/CT imaging in patients with diverse types of systemic amyloidosis. The study enrolled a total of 57 subjects, 50 of which had systemic amyloidosis, two of which were asymptomatic ATTR carriers, and five of which were healthy volunteers.
news & meetingsCombination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis PatientsUpdated research regarding the ANDROMEDA...
videos & visualsAmyloid Transthyretin (ATTR) Amyloidosis in the Nerves – ASG Webinar 3/7https://www.youtube.com/watch?v=IzC_yaqs...
people & placesKelsey Barrell, MDKelsey Barrell is an Assistant Professor...
people & placesUte HegenbartUte Hegenbart is a Senior Physician and ...
educationLong-Term Outcome of Patients with AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell TransplantationIn immunoglobulin light chain (AL) amylo...
educationSystemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic ReviewImportance: Many patients with systemic ...
videos & visualsGenetic Counseling for Hereditary TTR Amyloidhttps://www.youtube.com/watch?v=w97DLzdt...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.